## Abstract

The present provides a condensed pyridine compound (I) represented by the following formula:

$$\begin{array}{c|c}
 & R^3 \\
 & (CH_2)_n - B \\
 & R^2 \\
\end{array}$$
(I)

(wherein, R<sup>2</sup> represents

$$+N \longrightarrow T-R \longrightarrow +N \longrightarrow R^5 \longrightarrow -N \longrightarrow R^6$$

ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and

B represents

$$\left(\begin{array}{c}
R^7 \\
Q \\
R^9
\end{array}\right)
\left(\begin{array}{c}
C \\
C \\
Q
\end{array}\right)
\left(\begin{array}{c}
R^{11} \\
Q \\
R^{12}
\end{array}\right)$$

$$\begin{pmatrix}
O \\
(C H_2)p
\end{pmatrix}$$

$$\begin{pmatrix}
P^{14} \\
O
\end{pmatrix}$$

$$\begin{pmatrix}
NH \\
O
\end{pmatrix}$$

$$R^{15}$$
 $R^{16}$ 



its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

m \*3